Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs

Oral Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles